Aug 2026· Journal of Clinical Medicine· Vol 15· 0 citations· 27 references
Medicine
TL;DR
Survival outcomes in this cohort are markedly lower than in high-income countries, and improving survival requires complementing biological risk stratification with targeted strategies to overcome socioeconomic barriers and prevent treatment non-adherence.
Abstract
Background/Objectives: B-cell acute lymphoblastic leukemia (B-ALL) remains the most common pediatric malignancy. This study aimed to evaluate clinical outcomes in pediatric B-ALL in Southern Mexico and determine how socioeconomic vulnerabilities—specifically indigenous status and treatment non-adherence—independently drive relapse and compromise survival in a resource-limited setting. Methods: A retrospective cohort study was conducted, including 146 patients (0–17 years) treated between 2010 and 2024 using modified Total XIII and XV protocols. Survival was estimated via Kaplan–Meier. Independent prognostic factors for overall survival (OS) and relapse were identified using multivariable Cox proportional hazards models. Results: The 5-year OS was 50%, and event-free survival (EFS) was 37.6%. Survival varied significantly by clinical risk: 88% for low-risk, 77% for standard-risk, and 31% for high-risk patients. Relapse occurred in 45.8% of patients. Beyond established biological predictors like hyperleukocytosis and high-risk cytogenetics, socioeconomic vulnerabilities profoundly impacted outcomes. Documented treatment non-adherence significantly reduced 5-year OS (23.4% vs. 56.1%, p = 0.001) and disproportionately affected indigenous patients (55.5% vs. 10.1% in non-indigenous). Multivariable analysis identified indigenous status as an independent predictor of increased relapse hazard (HR = 1.89, p = 0.049), alongside male sex and high leukocyte count. Conclusions: Survival outcomes in this cohort are markedly lower than in high-income countries. The high incidence of relapse is deeply intertwined with local structural inequities. Improving survival requires complementing biological risk stratification with targeted strategies to overcome socioeconomic barriers and prevent treatment non-adherence.
Introduction Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, accounting for approximately 80% of childhood acute leukemia cases. Despite substantial improvements in survival in high-income countries, outcomes in Indonesia remain suboptimal. Methods This retrospective cohort study analyzed me...
D. Sari, Dewi Rosariah Ayu, R. M. Indra et al.· Frontiers in Pediatrics· 0 citations
Introduction Data on clinical outcomes and allogeneic stem cell transplantation for Latin American Philadelphia chromosome-negative acute lymphoblastic leukemia patients are limited. This study aimed to characterize this population and identify factors influencing overall survival among adolescents and adults with this...
M. M. Clavijo, J. Ruiz, Luciana Ferrari et al.· Hematology, Transfusion and...· 0 citations
Survival of adults with ALL in Latin America has improved compared with historical reports, but substantial disparities persist between public and private settings, and upfront dasatinib was associated with improved OS, primarily through lower non-relapse mortality rather than reduced relapse incidence.
W. F. Silva, M. Espinoza, L. Ferrari et al.· The Lancet Regional Health -...· 0 citations
Chronic lymphocytic leukemia (CLL) is a hematological malignancy of mature clonal B‐cells commonly affecting elderly patients. Novel targeted therapies have improved survival, with 5‐year overall survival (OS) approaching that of the general population. However, data from Sub‐Saharan Africa, including Tanzania, remain...
S. Saleh, Ahlam Nasser, Mwashungi Ally et al.· Hematological Oncology· 0 citations
Purpose Neuroblastoma is a heterogeneous pediatric malignancy with variable outcomes. This study aimed to evaluate survival outcomes and identify independent prognostic factors using a large population-based cohort. Methods The Surveillance, Epidemiology, and End Results (SEER) database was used to identify 863 patient...
Shruti Wadhwani, Nikita Wadhwani, V. Nagesh et al.· Frontiers in Medicine· 0 citations
In this real-world cohort of older patients with AML, no statistically significant differences in PFS or OS were observed between intensive and non-intensive treatment strategies, highlighting the relevance of functional status in individualized treatment selection.
Dila Elifsu Yuksekli, A. Bayar, Ceren Uzunoglu Guren et al.· Medicina· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.